The hematological malignancies classified as mixed lineage leukemias (MLL) harbor fusions of the MLL1 gene to partners that are members of transcriptional elongation complexes. MLL-rearranged leukemias are associated with extremely poor prognosis, and response to conventional therapies and efforts to identify molecular targets are urgently needed. Using mouse models of MLLrearranged acute myeloid leukemia, here we show that genetic inactivation or small-molecule inhibition of the protein arginine methyltransferase PRMT5 exhibit anti-tumoral activity in MLL-fusion protein-driven transformation. Genome-wide transcriptional analysis revealed that inhibition of PRMT5 methyltransferase activity overrides the differentiation block in leukemia cells without affecting the expression of MLL-fusion direct oncogenic targets. Furthermore, we find that this differentiation block is mediated by transcriptional silencing of the cyclin-dependent kinase inhibitor p21 (CDKN1a) gene in leukemia cells. Our study provides preclinical rationale for targeting PRMT5 using small-molecule inhibitors in the treatment of leukemias harboring MLL rearrangements.
INTRODUCTION MLL-fusion leukemias represent a paradigm for determining how epigenetic dysregulation leads to the corruption of transcriptional programs in cancer initiating cells. In these types of leukemia, the DNA-binding domain of the histone methyltransferase MLL1 is fused with one of several possible partners that are part of transcriptional complexes. 1, 2 MLL1 is the founding member of a family of histone methyltransferases and it directs the expression of genes essential for hematopoietic stem cell maintenance and homeostasis. 3 Hence, MLL fusions lead to deregulated expression of stem cell genes and this corrupted gene expression program enforces a differentiation block characteristic of these leukemias. Both hematopoietic stem cells and committed myeloid precursors are targets for MLL-fusion transformation and the gene signatures of these leukemic initiating cells combine features of both hematopoietic stem cell and myeloid precursor gene expression. 1, 2 It has become clear that tight and intricate epigenetic regulation takes place during transformation and several studies have focused on histone lysine methylation aiming at identifying epigenetic targets for the treatment of MLLtranslocated leukemias. 4 For example, we previously found that the histone methyltransferase MLL4 (KMT2D) is required for stem cell activity and an aggressive form of MLL-fusion acute myeloid leukemia (AML) harboring the MLL-AF9 oncogene. 5 However, less is known about the second major type of protein methylation, arginine methylation, in MLL-fusion protein-driven transformation.
Arginine methylation is a prevalent post-translational modification found on both nuclear and cytoplasmic proteins. Three distinct types of methylation are found on the guanidine group of arginine residues in mammalian cells: monomethylated, symmetrically dimethylated (SDMA) and asymmetrically dimethylated, with potential different functional consequences for each methyl state. These methyl states are catalyzed by a family of protein arginine methyltransferases, termed PRMTs. There are nine PRMTs -type I and type II enzymes catalyze the formation of a monomethylated intermediate, then type I PRMTs (PRMT1, 2, 3, 4, 6 and 8) further catalyze the production of asymmetrically dimethylated, while type II PRMTs (PRMT5 and 9) catalyze the formation of SDMA. 6 Of the nine PRMTs encoded in mammalian genomes, the type II protein arginine methyltransferase PRMT5 has been extensively characterized as a histone methyltransferase that modifies H4R3, H2AR3 and H3R8. [7] [8] [9] [10] [11] PRMT5 also methylates several non-histone proteins, [12] [13] [14] [15] [16] [17] thereby potentially affecting multiple signaling pathways. Lowering the levels of PRMT5 is associated with reduced cell growth, whereas PRMT5 overexpression causes cellular hyperproliferation. 10, 18 Overexpression or increased PRMT5 enzymatic activity is observed in several cancers, including lymphoma and leukemia. 10, 18, 19 A recent study suggested an important role for PRMT5 in lymphomagenesis triggered by multiple oncogenic drivers with knockdown experiments showing evidence for a strong selection to maintain PRMT5 expression in MLL-AF9 cells. 20 In vitro and in vivo efficacy of a selective PRMT5 inhibitor (PRMT5i), EPZ015666 (also called GSK3235025) in mouse models of mantle cell lymphoma was recently reported. 21 Yet, another recent study using a smallmolecule inhibitor of PRMT5, describes a positive feedback loop between PRMT5 and BCR-ABL in chronic myeloid leukemia. 22 Although we have recently described the effects of conditional deletion of PRMT5 in mouse hematopoietic stem/progenitor cells and characterized the role of PRMT5 in normal hematopoiesis, 23 similar studies have not been performed in the context of MLLrearranged leukemia. Using mouse models of these aggressive leukemias, here we establish that genetic deletion of PRMT5 or inhibition of PRMT5 methyltransferase activity with a smallmolecule inhibitor impairs MLL-rearranged leukemia in vitro and in vivo, without affecting the expression of MLL-fusion direct oncogenic targets. Furthermore, we show that PRMT5 is required to enforce the differentiation block characteristic of these leukemias by mediating silencing of CDKN1a (p21). Our study suggests that PRMT5 inhibition holds a therapeutic potential in MLL-rearranged leukemia. 
MATERIALS AND METHODS

Cell culture
Mouse MLL-ENL/Nras G12D cells were kindly provided by I Zuber. MLL-AF9 cells were derived from bone marrow obtained from terminally ill recipient mice, and were cultured in RPMI-1640 (Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. BOSC cells were grown in DMEM (Gibco-Invitrogen) supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. All human leukemic cell lines were cultured in RPMI-1640 supplemented with 10% FBS, 5% penicillin/streptomycin and 5% Lglutamine (100 mM), except Kasumi-1 cells, which were cultured in 20% FBS. Human leukemia lines were provided by the IACS (Institute for Applied Cancer Science) at The University of Texas MD Anderson Cancer Center. To generate knockdown cell lines, BOSC cells were grown to 80% confluence and transfected with short hairpin RNA (Transomic Technologies, Huntsville, AL, USA) targeting the gene required by the experiment and helper plasmid (pCL-Eco). Transfection was carried out using XtremeGene9 DNA transfection reagent (Roche, Indianapolis, IN, USA). After 48 h, the viral supernatant was collected and infected into MLL-ENL/ Ras G12D cells using 5 ng/ml interleukin-3, 5 ng/ml interleukin-6, 100 ng/ml stem cell factor and 10 μg/ml polybrene in the culture media. After 24 h, virus was removed and media was replaced with fresh media. Cells were allowed to grow for 72 h and selection was performed with Geneticin (G418, Life Technologies, Carlsbad, CA, USA) at 1 mg/ml for 5 days. After selection, cells were subsequently cultured with 0.2 mg/ml G418. To perform proliferation assays, cells in log phase were cultured at a seeding density of 0.25 million cells per ml in 2-4 ml of media depending on the yield required at the end of the experimental period. The PRMT5 inhibitor was dissolved in DMSO at the concentration of 5 mM and the cells were treated with the compound at the final concentration of 5 μM. The cells for control were treated with equal concentration of DMSO. The cells were treated again on day 2. At the end of each treatment period, cells were stained with acridine orange/propidium orange and counted using the Nexcelom Cellometer (Lawrence, MA, USA) and acridine orange/propidium Iodide staining. Relative proliferation rates were calculated by normalizing to the rate of DMSO-treated cells.
May-Grünwald-Giemsa cytospin staining and microscope imaging acquisition Cells at the end of the experimental period were collected by centrifugation (1500 r.p.m., 5 min) and cell pellets were re-suspended in PBS with 2% FBS. A total number of 75 000 cells were cytospun onto glass slides at 800 r.p.m. for 5 min. May-Grünwald (Sigma) and Giemsa (Sigma) stainings were performed according to manufacturer's protocols. Images were collected using Aperio CS imaging platform (Leica Biosystems, Buffalo Grove, IL, USA) with a × 20 objective at a spatial sampling of 0.47 μm per pixel. Whole-slide images (WSI) were viewed and processed using Spectrum ImageScope software (version 10.2.2.2315).
Flow cytometry
For all, flow cytometry analysis cells were stained in PBS (Corning Cellgro, Manasses, VA, USA) supplemented with 2% of inactivated FBS (Gemini BioProducts, Sacramento, CA, USA). The following antibodies were used: B220 PE, CD11b PE or APC, CD11C PE or APC, CD4 PE, CD8 PE, NK1.1 PE, Ter119 PE, CD3 PE, c-Kit APC or biotin-conjugated (BD Biosciences, San Jose, CA, USA). Sca-1 PEcy7, streptavidin-APC (eBiosciences, Carlsbad, CA, USA) and streptavidin Pacific blue (Invitrogen, Carlsbad, CA, USA) were used. DAPI was used to exclude dead cells. Edu incorporation assays were performed according to manufacturer's protocol (Invitrogen, Click-iT Edu Alexa Fluor 647 Imaging kit), with cells pulsed with Edu for 30 min. Cells were co-stained with DAPI for DNA content measurement. Annexin V apoptosis staining was performed according to manufacturer's protocol (BD Pharmingen, San diego, CA, USA, APC Annexin V). All flow cytometry was performed on a LSR Fortessa (BD Biosciences).
Western blot analysis
Cells were lysed in radioimmunoprecipitation buffer with protease inhibitor cocktail tablet (Roche), sonicated on ice and spun at 4°C. The supernatant was assayed for protein concentration by BCA (Pierce, Carlsbad, CA, USA). Protein of 30 μg was resolved by Sodium Dodecyl Sulphate polyacrylamide gel electrophoresis and transferred to nitrocellulose for blotting. Blots were blocked with 3% milk in phosphate buffered saline with tween20 solution at room temperature and then incubated with primary antibody (SDMA: cat#13222S; Cell Signaling Technology, Beverly, MA, USA, p21: cat# SC6246; Santa Cruz Biotechnology, Dallas, TX, USA, p53: cat# SC126; Santa Cruz Biotechnology, PRMT5: cat# 61001; Active motif, Carlsbad, CA, USA, β-actin: cat# A1978; Sigma). All antibodies were prepared at dilutions according to manufacturer's protocol in blocking buffer at 4°C overnight and secondary antibody (Sheep Anti-Mouse: cat# NXA931; GE Healthcare, Piscataway, NJ, USA and Goat Anti-Rabbit: cat# NA934; GE Healthcare; prepared at 1:10 000 in blocking buffer) at room temperature for 2 h.
Quantitative PCR Cells were spun down and washed once with cold PBS, then RNA was isolated with a Qiagen RNeasy kit (cat# 74104; Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Total RNA of 1 μg was treated with amplification-grade DNaseI (cat# 79254; Qiagen) according to the manufacturer's protocol, and reverse-transcribed with the SuperScriptIII Supermix system (cat# 11752-250; Invitrogen) according to the manufacturer's protocol. Messenger RNA levels were analyzed via quantitative PCR (qPCR) analysis using the Bio-Rad (Carlsbad, CA, USA) Supermix according to manufacturer's protocol. Reactions were performed on an ABI 7900HT Fast Real-Time PCR system (ABI 7900HT Fast Real-Time PCR System, Foster City, CA, USA). Samples were normalized to transcripts encoding Gapdh.
p21: 5′ CTGGGAGGGGACAAGAG and GCTTGGAGTGATAGAAATCTG 3′ Gapdh: 5′ TGACGTGCCGCCTGGAGAAA and AGTGTAGCCCAAGATG CCCTTCAG 3′ 24 By reads, the overall mapping rate is 85-96%. Fragments of 76-94% have both ends mapped to the mouse genome. Differential expression: the number of fragments in each known gene from RefSeq database (downloaded from UCSC Genome Browser on 17 July 2015) was enumerated using htseq-count from HTSeq package (version 0.6.0). 25 Genes with o 10 fragments in all the samples were removed before differential expression analysis. The differential expression between conditions was statistically assessed by R/Bioconductor package DESeq (version 1.16.0). 26 Genes with FDR (false discovery rate) ⩽ 0.05, fold change ⩾ 2 and length 4200 bp were called as differentially expressed. Landscape profile of RNA-seq signal: for the fragments that have both ends mapped, the first reads were kept. Together with the reads from the fragments that have only one end mapped, every read was extended to its 3′ end by 200 bp in exon regions. For each read, a weight of 1/n was assigned, where n is the number of positions the read was mapped to. The sum of weights for all the reads that cover each genomic position was rescaled to normalize the total number of fragments to 1 M and averaged over 10 bp resolution. The normalized values were displayed using UCSC genome browser (http://genome.ucsc.edu/). Gene clustering and heatmap: hierarchical clustering was performed by hclust function in R using gene expression values estimated by DESeq. The expression values of each gene across samples were centered by median and scaled by s.d. before clustering. Euclidean distance and ward.D2 clustering method were used. The heatmap was plotted by heatmap.2 function in R. Gene set enrichment analysis (GSEA): GSEA was performed by GSEA software (version 2.2.1). 27 The expression values estimated by DESeq for all the genes were taken as the expression data set. The permutation type was set as 'gene_set' and all the other parameters were set as default.
Chromatin immunoprecipitation analysis
Cells were grown to 80% confluence, washed twice in warm PBS, trypsinized and re-suspended in warm media containing 0.1 volume cross-linking solution. 28 ChIP reactions were performed as described previously 29 followed by DNA purification with a Qiaquick PCR Cleanup kit (cat# 28106; Qiagen). Antibodies used include: anti-H4R3me2s (cat# ab5823; Abcam, Cambridge, MA, USA), anti-H3K4me3 (cat# 04-745; Millipore, Billercia, MA, USA), anti-H3K27me3 (cat# 07-449; Millipore) and anti-p53 (cat#2524, Cell Signaling Technology). Antibodies for modified histones and p53 were added at 1-5 μg /ChIP reaction. The concentration of IgG (cat# 12-370; Millipore) was adjusted from 1-5 μg as appropriate. For qPCR analysis, real-time PCR was performed with the iTaq SYBRgreen Supermix (cat# 172-5121; Bio-Rad) according to manufacturer's protocol. Primer sequences were derived from the enhancer and promoter regions of CDKN1a. Reactions were performed on an ABI 7900HT Fast Real-Time PCR system.
Statistical analyses
Multiple independent biological experiments were performed to assess the reproducibility of experimental findings. Each group is presented by mean ± s.e. To compare two experimental groups, statistical tests were conducted using R statistical language (http://r-project.org). Unpaired, twotailed t-tests were used for all analyses. For ex vivo experiments, multiple independent biological replicates were used. For leukemia transplantation, six to eight recipients per group were used since variation among experiments was low. Animals were placed in different experimental groups and disease development was assessed blindly without prior knowledge of genotype. The significance between the longevity of cohorts was assessed by Kaplan-Meier survival analysis and log-rank (Mantel-Cox) tests. P-values o0.05 were considered significant to reject the null hypothesis. No randomization was used in any experiment. Statistical analysis of RT-qPCR and ChIP-qPCR data: for analysis of gene expression, the measured cycle threshold experimental values for each transcript were compiled and normalized to the reference gene glyceraldehyde 3-phosphate dehydrogenase (Gapdh-NM_008084). Normalized expression levels were calculated using the DDCT method described previously. 30 Values from these calculations were transferred into the statistical analysis program GraphPad (GraphPad Software, Inc., La Jolla, CA, USA) and unpaired, two-tailed t-tests were run to assay differences between control and treated cells. For samples with P-values o0.05, we have marked statistically significant differences with asterisks. For quantitative analysis of candidate gene regulatory region enrichment in MLL-ENL/Nras G12D AML cells, ChIP samples were normalized to 1% input, and data were analyzed using the formula previously described. 31 The cumulative mean from each of the three independent experiments was calculated and the s.e.m. derived. The statistical analysis package GraphPad was used to measure statistical significance between the percent input for the control and PRMT5i-treated samples using unpaired, two-tailed t-tests to assay differences between control and treated cells.
Data availability
All raw and normalized RNA-Seq data that support the findings of this study have been deposited in the GEO SuperSeries under accession number GSE100820.
RESULTS
Loss of PRMT5 impairs the initiation and maintenance of MLL-rearranged leukemia Homozygous deletion of PRMT5 results in early embryonic lethality. 32 To investigate the role of PRMT5 in MLL-fusion leukemia, we developed a conditional knockout mouse model by crossing mice that carry loxP sites flanking exon 7 of PRMT5 (PRMT5 flox/flox ), 23 with transgenic mice expressing interferoninducible MxCre (Mx1-Cre) or estrogen receptor (ER)-inducible cre (ER-Cre). Deletion of PRMT5 can be induced by polyinosinic: polycytidylic acid (poly:IC) or tamoxifen administration, respectively.
We have previously shown that the lysine methyltransferase MLL4 is required for the initiation and maintenance of AML in a mouse model of human AML containing a translocation between MLL1 and AF9 genes. 5, 33 To determine whether the arginine methyltransferase PRMT5 modifies MLL-AF9 leukemia, we first introduced MLL-AF9 into PRMT5 flox/flox and PRMT5 flox/ flox ER-Cre bone marrow hematopoietic stem/progenitor cells with a retrovirus marked with green fluorescent protein (GFP) (MLL-AF9-IRES-GFP). 33 After sorting, GFP + cells were cultured in semi-solid media with 4-hydroxytamoxifen (4-OHT). We found that PRMT5 deletion in vitro (Supplementary Figure 1A) greatly decreased the number of colony-forming units scored after 7 days (Figure 1a) . To evaluate the role of PRMT5 in leukemia development in vivo, we transplanted MLL-AF9-transduced fetal liver cells isolated from E14.5 PRMT5 flox/flox , PRMT5 flox/+ Mx1Cre+ and PRMT5 flox/flox Mx1Cre+ embryos into sublethally irradiated recipient mice. Subsequently, PRMT5 was deleted by administering poly (I:C) injections 2 weeks after the transplant. All animals in the control and heterozygous groups died of AML in o 90 days (Figure 1b (left), Supplementary Figure 1B) . However, more than half of the animals that received MLL-AF9 transformed PRMT5 flox/flox Mx1Cre+ cells survived 4120 days without showing signs of leukemia (Figure 1b, left) . Leukemias that did develop in these animals were derived from cells that failed to completely delete PRMT5, as shown by the levels of PRMT5 protein present in the GFP + leukemia cells isolated from these animals (Figure 1b fl/+ MxCre+ heterozygous cell recipients increased from around 3% at week two to 60% at week eight ( Supplementary  Figures 1D and E) . Thus, PRMT5 appears to play an essential role in the initiation of MLL-AF9-mediated leukemia in vivo.
We next determined the role of PRMT5 in the maintenance of established MLL-AF9 leukemia. PRMT5 flox/flox and PRMT5
flox/flox
Mx1Cre+ AML was isolated from moribund mice (without poly (I:C) injections), and spleen cells from these primary leukemias (90% GFP + ) were injected into sublethally irradiated secondary recipients. Deletion of PRMT5 was induced in transplanted animals when the frequency of GFP + cells in the peripheral blood reached 1-30%. One week after poly (I:C) injection, mice that received PRMT5 flox/flox Mx1Cre+ cells had significantly lowered the levels of GFP + cells in the peripheral blood (from 12 to 3%). In contrast, the levels of GFP + cells in the peripheral blood of PRMT5 flox/flox control cell recipients increased from 7 to 80%, and these animals succumbed to AML in the subsequent week (Supplementary Figures 1F and G and Figure 1c) . PRMT5 deletion did prolong the average survival from 3 weeks in the control group to 7 weeks in the PRMT5 flox/flox Mx1Cre+ group. Together, our data demonstrate that PRMT5 is required for the initiation and maintenance of MLLrearranged leukemia.
AML growth is sensitive to PRMT5 inhibition The recent identification of a potent small-molecule PRMT5 inhibitor, EPZ015666, 21 together with our data showing that genetic loss of PRMT5 impairs the initiation and maintenance of MLL-fusion AML (Figure 1 ) prompted us to investigate the sensitivity of leukemia cells to small-molecule inhibition of PRMT5 activity. Proliferation of mouse myeloid leukemia cells was notably sensitive to PRMT5 inhibition, as compared to proliferation of murine CH12 B-cell lymphoma cells (Figure 2a) . We also examined growth-inhibitory effects of EPZ015666 in established human AML leukemia lines representing diverse disease subtypes. We observed growth-suppressive activity in all AML lines, with MLLfusion translocation positive MOLM13 cells showing the most sensitivity. We also tested a T cell-leukemia line (Jurkat) that showed minimal sensitivity to the compound (Figure 2b) . Because leukemic cells expressing MLL-fusions appear more sensitive to the inhibition of PRMT5, we used a well-characterized mouse model of AML induced by overexpression of the MLL-ENL fusion protein and oncogenic Ras (Nras G12D ) [34] [35] [36] [37] to further investigate the mechanism of dependency. EPZ015666 treatment triggered cell cycle arrest (Figures 2c and d) and increased the frequency of apoptotic cells (though not enough to reach statistical significance in the apoptosis assays) in MLL-ENL/Nras G12D cells (Figure 2e ). Small-molecule inhibition of PRMT5 with EPZ015666 correlated ) groups (without poly (I:C) injection) were transplanted into sublethally irradiated mice and poly (I:C) injections were given to these mice when the peripheral blood GFP + cells reached 10-20%. The survival curve of the secondary transplanted mice is shown. n = 5-6. **P o0.01. Figure 2A) . Together, these data show a requirement for PRMT5 in AML growth that can be effectively inhibited by targeting the PRMT5 methyltransferase activity with EPZ 015666.
EPZ015666 has anti-leukemia effects as a single agent in vivo
The MLL-ENL/Nras G12D model has proven particularly suitable to test the effect of small-molecule inhibitors of epigenetic pathways in MLL-fusion AML.
37,38 MLL-ENL fusions are co-expressed with enhanced green fluorescence protein and oncogenic Nras G12D is co-expressed with luciferase to enable imaging of the leukemias by bioluminescence. 37 Since EPZ015666 is orally bioavailable, 21 mice transplanted with MLL-ENL/Nras G12D leukemia cells were administered by oral gavage a dose of 150 mg/kg b.i.d. of this drug. We chose this dose based on previous studies using EPZ015666 in mantle cell lymphoma models. Higher doses were shown to confer increased levels of toxicity in treated animals. 21 EPZ015666 administration resulted in a significant delay in disease progression and increased survival (Figures 3a-c) . The advantage in median survival is similar to that reported using this aggressive AML mouse model following treatment with the bromodomain and extra terminal protein (BET) small-molecule inhibitor JQ1 in similar settings. 38 We observed a profound reduction in the symmetric dimethylation of argininecontaining substrates (SDMA) upon EPZ015666 treatment, as shown by immunoblot of cells isolated from the spleens of moribund mice (Supplementary Figure 3A) . Consistent with published findings, EPZ015666 was well tolerated in mice at the indicated dose 21 and had no impact on hematopoiesis when administered to control animals (Supplementary Figures 3B and C  and Supplementary Figure 4) . We conclude that EPZ015666 has specific anti-leukemia effects as a single agent in vivo.
PRMT5 inhibition leads to myeloid differentiation and leukemic stem cell-depletion without affecting the expression of MLL-fusion oncogenic targets A hallmark of MLL-fusion AML is the block in myeloid differentiation and the acquisition of aberrant self-renewal properties with a concomitant expression of stem cell markers. Previous studies have implicated PRMT5 in promoting cell cycle and inhibiting apoptosis, 20 ,39 therefore, we considered whether PRMT5 knockdown or PRMT5 inhibition affected the differentiation status of MLL-fusion leukemia cells. PRMT5-deficient MLL-ENL/Nras G12D leukemia cells (PRMT5 shRNAi, 490% efficiency, Supplementary Figure 5A ) or treatment of MLL-ENL/ Nras G12D leukemia cells with EPZ015666 resulted in the morphologic change of monomyelocytic blasts to macrophage-like cells (Supplementary Figures 5B and C and Figure 4a ). These Targeting PRMT5 in MLL-fusion leukemias S Kaushik et al morphologic changes were accompanied by increased expression of the myeloid differentiation marker Mac1 (Integrin αM) and decreased expression of c-Kit, a stem cell marker associated with MLL-fusion leukemic stem cells (LSCs) 40 (Supplementary Figure 5D) . To further determine whether the inhibition of PRMT5 methyltransferase activity compromises the LSC compartment, we performed GSEA of RNA-seq data from 72 htreated DMSO and EPZ015666 MLL-ENL/Nras G12D leukemia cells. We observed a significant upregulation of macrophage development-associated genes upon PRMT5 inhibition (Figure 4b, left) . MLL-fusion leukemia cells are comprised of LSCs and non-self-renewing leukemia cells. These two populations can be discriminated based on a well-defined gene expression signature. 40 GSEA revealed a global downregulation of this gene signature in cells treated with EPZ015666 compared to DMSO-treated cells (Figure 4b, right) . Together, our data show that PRMT5-dependent methylation is required to maintain a LSC population and to enforce the myeloid differentiation block characteristic of MLL-fusion leukemias.
Our genome-wide analysis showed that EPZ015666 treatment resulted in downregulation of 325 genes and upregulation of 751 genes (Figure 4c , left, FDR ⩽ 0.05, fold change ⩾ 2). However, 96% of MLL-fusion direct targets 41 were not affected by PRMT5 inhibition (Figure 4c, right) , such as the master MLL-fusion oncogenic factors HOXA9 and MEIS1. This suggests that the LSC signature and LSC self-renewal are compromised by an alternative pathway.
PRMT5 inhibitor-induced differentiation of leukemic cells is dependent on p21
We previously uncovered a connection between cell cycle checkpoint pathways and the 'stemness' vs differentiation status of MLL-fusion cells. 5 Using an MLL-AF9 mouse model, we showed that DNA damage induces the differentiation of MLL-fusion leukemia blasts to myeloid cells, and that cell-cycle exit and differentiation of MLL-AF9 cells is coupled to activation of the cell cycle inhibitor p21 (CDKN1a for gene name), as p21-deficient leukemia cells are resistant to DNA damage-induced differentiation. 5 Moreover, previous studies have shown that knockdown of p21 in MLL-transformed cells significantly decreases leukemia latency, validating p21 as a biologically important target in vivo. 42 Interestingly, the gene encoding p21, CDKN1a, was among the top 20 genes most significantly upregulated in our PRMT5-inhibitor RNA-seq data set (for the list of the 50 most significantly upregulated and downregulated genes, see Supplementary Tables S1 and S2 ). We confirmed the upregulation of CDKN1a mRNA by RT-qPCR upon EPZ015666 treatment (Figures 5a and b ) that correlated with a significant increase in p21 protein levels (Supplementary Figure 6A) . To directly determine if p21 is required for PRMT5 inhibitor-induced differentiation of leukemia cells, we treated MLL-ENL/Nras G12D p21-deficient cells (CDKN1a shRNA, 490% efficiency, Supplementary Figure 6B ) with EPZ015666 and found that p21-deficient MLL-ENL/Nras G12D cells were resistant to PRMT5-inhibitorinduced differentiation (Figure 5c ). shown. ****P o0.0001. Error bars represent s.e. (c) Kaplan-Meier survival curves of control and EPZ015666-treated mice. Statistical significance was calculated using a log-rank test. n = 8 for 0.5% methylcellulose-treated and n = 6 for EPZ015666-treated animals.
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Silencing of CDKN1a by PRMT5 in leukemia cells Using a mouse model of T-cell lymphoma/leukemia driven by a constitutively nuclear mutant of cyclin D1 (D1T286A), a recent study showed that PRMT5 overexpression cooperates with mutant cyclin D1 to drive lymphomagenesis. Coexpression of PRMT5 with D1T286A antagonized induction of a majority of the genes induced by D1T286A alone, including CDKN1a. 20 PRMT5 has also been associated with CDKN1a silencing in muscle stem cells. 43 On the basis of these previous findings, we hypothesized that CDKN1a is silenced by PRMT5 in leukemia cells. To evaluate in vivo interactions taking place in well-characterized regulatory regions of the CDKN1a gene 44, 45 (Supplementary Figure 6C) , we employed ChIP followed by qPCR (ChIP-qPCR) to demonstrate the location of PRMT5-associated repressive H4R3 symmetric dimethylation marks (H4R3me2s). [7] [8] [9] [10] We detected significant enrichment of H4R3me2s to the enhancer region, proximal promoter region and the p53-binding site of CDKN1a. Inhibition of PRMT5 methylation activity upon EPZ015666 treatment resulted in a marked reduction of H4R3me2s in these regions (Figure 6a ), correlating with a derepression of the chromatin state evidenced by an increase in H3K4me3 at the promoter ( Figure 6b ) and decreased nucleosome occupancy at the transcriptional start site (Figure 6c ). Taken together, our data show that PRMT5 promotes epigenetic changes that result in transcriptional silencing of CDKN1a in leukemia cells. CDKN1a is a well-known target of p53 and PRMT5 has been shown to negatively regulate p53 function. 17, 20, [46] [47] [48] We did not detect alterations in Trp53 mRNA (Supplementary Figure 7A) or protein levels upon EPZ015666 treatment (Supplementary Figure 7B) , thus, PRMT5-mediated repression of CDKN1a expression is not due to decreased Trp53 mRNA or protein levels. We next measured the levels of CDKN1a in MLL-fusion p53-deficient cells in the presence or absence of EPZ015666. Although in Wild Type cells, we could readily detect an increase in CDKN1a mRNA levels upon PRMT5 inhibition, the levels of CDKN1a remained the same in p53-deficient leukemia cells (Figure 7a) . Moreover, the p53-deficient cells were refractory to EPZ015666-induced differentiation (Figure 7b) , confirming that the block in differentiation upon PRMT5 inhibition is dependent on re-activation of CDKN1a and this is dependent on p53 activity. These data are in agreement with previous reports showing that PRMT5 negatively regulates p53 function. 17, 20 Taken together, these data show that the effects of PRMT5 inhibition in MLL-leukemia cells are dependent on p53 activity and the transcriptional regulation of its target CDKN1a.
DISCUSSION
Arginine methylation is becoming increasingly appreciated as an important regulator of cellular processes affecting cell growth, proliferation and differentiation. 49 In recent years, multiple studies have implicated several members of the PRMT family in cancer. 49 Importantly, a study using a MLL-rearranged AML mouse model to perform CRISPR-Cas9 screens identified PRMT1 and PRMT5 as epigenetic vulnerabilities in these leukemias. 50 Other studies further revealed the role of PRMT1 in MLL-fusion leukemia and provided evidence for a therapeutic potential of small-molecule inhibition of PRMT1 methyltransferase activity. 51, 52 PRMT1 is necessary but not sufficient for transformation by MLL fusions and, together with KDM4C, an H3K9 demethylase, regulates the expression of MLLfusion oncogenic targets (for example, HoxA9). 52 We have recently described the effects of conditional deletion of PRMT5 in mouse hematopoietic stem/progenitor cells and characterized the role of PRMT5 in normal hematopoiesis. 23 These studies show that PRMT5 is essential to sustain adult hematopoiesis, as deletion of PRMT5 impairs steady-state hematopoiesis, colony-forming capacity and bone marrow reconstitution. However, similar studies were not performed in the context of leukemia. We now show that conditional genetic deletion of PRMT5 or small-molecule inhibition of PRMT5 activity with the small-molecule inhibitor EPZ015666 impair leukemia development in mouse models of MLL-rearranged AML. Our studies establish an important role for PRMT5 in enforcing the differentiation block characteristic of MLL-fusion leukemias. We found that this differentiation block imposed by PRMT5 is dependent on the cyclin-dependent kinase inhibitor p21 and that PRMT5 inhibition in leukemia cells causes an upregulation of the gene encoding cells were treated with 5 μM EPZ015666 for 4 days, and the frequency of blasts was determined and normalized to DMSO-treated cells in independent experiments. We counted the number of blasts in May-Grünwald/Giemsa stained MLL-ENL/NRas G12D cells (in cytospin slides as in Figure 4a ) by microscopy. For each experimental condition, we counted the number of blasts per 100 cells in three different fields of the cytospin slides. The bar graphs show the blast counts in PRMT5i-treated cells normalized to DMSO-treated cells (blue lines). **P o0.01.
Targeting PRMT5 in MLL-fusion leukemias S Kaushik et al p21 (CDKN1a). We find that PRMT5 mediates chromatin modifications associated with transcriptional silencing of the CDKN1a locus. Moreover, we also find that differentiation of MLL-rearranged cells and upregulation of CDKN1a upon PRMT5 inhibition require p53 activity. The epigenetic silencing of CDKN1a by PRMT5-dependent H4R3me2 activity and the p53 dependency are not mutually exclusive. Rather, our data lead us to suggest that both mechanisms act in MLL-rearranged leukemia cells to enforce the differentiation block by repressing CDKN1a. Importantly, although PRMT5 inhibition leads to de-repression of CDKN1a, it does not affect the expression of MLL-fusion direct oncogenic targets, contrary to PRMT1. +/+ and p53 −/− MLL-AF9 leukemia cells were treated with 5 μM EPZ015666 for 4 days, and the frequency of blasts was determined and normalized to DMSO-treated cells in independent experiments. We counted the number of blasts in May-Grünwald/Giemsa stained MLL-ENL/NRas G12D cells (in cytospin slides as in Figure 4a ) by microscopy. For each experimental condition, we counted the number of blasts per 100 cells in three different fields of the cytospin slides. The bar graphs show the blast counts in PRMT5i-treated cells normalized to DMSO-treated cells (blue lines). *P o0.05.
Several small-molecule inhibitors have been developed to target the epigenetic machinery co-opted by MLL-fusions, [53] [54] [55] [56] and some of these therapies are promising and currently being evaluated in clinical trials, for example, small-molecule inhibitors of the histone methyltransferase DOT1L. 53 Many of these epigenetic targets are required for the expression of MLL-fusion target genes. Since we found that PRMT5, however, enforces the differentiation block of MLL-fusion cells by an alternative mechanism, as PRMT5 inhibition did not affect the expression of MLL-fusion targets (Figure 4c, right) , our studies suggest that combining PRMT5 inhibitors with other targeted drugs may have promising therapeutic applications.
In summary, we found an important role for PRMT5 in enforcing the differentiation block of MLL-rearranged leukemias trough transcriptional silencing of CDKN1a. In addition, our studies pave the way for the use of PRMT5 small-molecule inhibitors in a clinical setting, as single agents or in combination with drugs that abrogate the transcription of MLL-fusion direct targets.
